"SMARCB1 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A component of the SWI-SNF CHROMATIN REMODELING complex that functions as a PROTEIN PHOSPHATASE 1 regulator and to stabilize CHROMATIN at PROMOTER REGIONS. It is important for regulating CELL PROLIFERATION and CELL DIFFERENTIATION. Mutations in the SMARCB1 gene are associated with malignant RHABDOID TUMORS.
| Descriptor ID |
D000071796
|
| MeSH Number(s) |
D12.776.260.716 D12.776.660.235.650 D12.776.664.235.900 D12.776.930.809
|
| Concept/Terms |
SMARCB1 Protein- SMARCB1 Protein
- Integrase Interactor 1 Protein
- BAF47 Protein
- SNF5 Homolog Protein
- Swi-Snf-Related Matrix-Associated Actin-Dependent Regulator Of Chromatin Subfamily B Member 1
- Swi Snf Related Matrix Associated Actin Dependent Regulator Of Chromatin Subfamily B Member 1
- BRG1-Associated Factor 47 Protein
- BRG1 Associated Factor 47 Protein
|
Below are MeSH descriptors whose meaning is more general than "SMARCB1 Protein".
Below are MeSH descriptors whose meaning is more specific than "SMARCB1 Protein".
This graph shows the total number of publications written about "SMARCB1 Protein" by people in this website by year, and whether "SMARCB1 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "SMARCB1 Protein" by people in Profiles.
-
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors. Clin Cancer Res. 2025 Feb 17; 31(4):628-638.
-
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. Nat Commun. 2024 Feb 14; 15(1):1373.
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
-
Constitutional balanced translocations involving SMARCB1: A rare cause of rhabdoid tumor predisposition syndrome. Genes Chromosomes Cancer. 2024 01; 63(1):e23195.
-
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance. Nat Commun. 2023 05 26; 14(1):3034.
-
SMARCB1 regulates the hypoxic stress response in sickle cell trait. Proc Natl Acad Sci U S A. 2023 05 23; 120(21):e2209639120.
-
Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. Otolaryngol Head Neck Surg. 2023 08; 169(2):435-440.
-
Heterotopic SMARCB1-deficient high-grade transformed/dedifferentiated acinic cell carcinoma and sine-qua-non radiology- pathology with TNM challenge. Ann Diagn Pathol. 2022 Apr; 57:151900.
-
Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021 05 15; 27(10):2879-2889.
-
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432.